Table 2 Clinical parameters of CRC patients by M5 category
M5 category | Low (n = 74) | Moderate (n = 206) | High (n = 53) | P value |
|---|---|---|---|---|
Age (years, range) | 61 (38–81) | 62 (28–87) | 68 (40–83) | 0.0656 |
Sex (male/female) | 23/51 | 79/127 | 22/31 | 0.4324 |
BMI (kg/m2) | 24.63 ± 2.79 | 24.33 ± 3.28 | 24.03 ± 3.33 | 0.568 |
Smoking (n, %) | 10 (13.5%) | 32 (15.5%) | 5 (9.4%) | 0.08367 |
Drinking (n, %) | 35 (47.3%) | 78 (37.9%) | 8 (15.1%) | 0.001077 |
ASA classification | ||||
 1 | 27 (36.5%) | 70 (34.0%) | 13 (24.5%) | 0.1786& |
 2 | 44 (59.5%) | 122 (59.2%) | 32 (60.4%) | |
 3 | 3 (4.1%) | 14 (6.8%) | 8 (15.1%) | |
CEA-high (n, %) | 9 (12.2%) | 34 (16.9%) | 30 (57.7%) | 0.0001248 |
Comorbidity (n, %) | 42 (56.8%) | 99 (48.1%) | 34 (64.2%) | 0.07785 |
 Hypertension | 36 (48.6%) | 68 (33%) | 22 (41%) | 0.04865 |
 Type 2 diabetes | 10 (13.5%) | 44 (21.4%) | 15 (28.3%) | 0.119 |
 Pulmonary disease | 6 (8.1%) | 15 (7.3%) | 2 (3.8%) | 0.644 |
Medication (n, %) | 43 (58.1%) | 104 (50.5%) | 35 (66.0%) | 0.1042 |
 Anti-hypertensive | 31 (42.9%) | 71 (34.5%) | 24 (45.3%) | 0.235 |
 Anti-diabetic | 7 (9.5%) | 39 (18.9%) | 12 (22.6%) | 0.08794 |
 Anti-inflammatory | 7 (9.5%) | 24 (11.7%) | 11 (20.8%) | 0.1477 |
Tumor location | ||||
 Proximal colon | 22 (29.7%) | 38 (18.4%) | 8 (15.1%) | 0.09491& |
 Distal colon | 29 (39.2%) | 107 (51.9%) | 30 (57.7%) | |
 Rectum | 22 (29.7%) | 60 (29.1%) | 13 (24.5%) | |
Tumor stage | ||||
 0,1 | 23 (31.1%) | 50 (24.3%) | 3 (5.7%) | 0.002322& |
 2 | 19 (26.8%) | 67 (32.5%) | 16 (30.2%) | |
 3 | 26 (35.1%) | 63 (30.6%) | 19 (35.8%) | |
 4 (M1) | 6 (8.1%) | 26 (12.6%) | 15 (28.3%) | |
Lym. Inv. (n, %) | 18 (24.3%) | 62 (30.1%) | 18 (34.0%) | 0.4769 |
MSI (n/N, %) | 14/66 (21.2%) | 23/188 (12.2%) | 3/53 (5.7%) | 0.00797 |
K-ras (n, %) | 22 (33.3%) | 60 (33.0%) | 19 (38.0%) | 0.8157 |